Primary objective is to assess the relationship between changes from serum biomarkers observed after 1 month of Saizen® therapy and change in height, weight after up to 5 years of treatment with Growth Hormone in children with Growth Hormone Deficiency (GHD) and Turner Syndrome (TS).

This study is an observational study that will collect data from patients enrolled in a previous study (PREDICT, NCT 00256126). Data such as auxological parameters (height, weight, Tanner stage, bone age will be collected as well as GH treatment use (including dose and adherence to the treatment).

Because for some countries the start of this long term follow up study will take place more than one year after subjects have completed the initial study (PREDICT) retrospective data may be collected (if subjects agree) as well as prospective data.

When available laboratory parameters such as IGF-1, IGFPB-3, fasting glucose, fasting insulin, TSH and T4 will also be collected.

This data will be collected yearly during the normal follow up visits during 5 years.

Inclusion Criteria:

• Have completed the PREDICT study (NCT 00256126)
• Followed up at least 1 year when still under treatment after completion of PREDICT Trial
• Parent's or guardian's written consent given before any data collection

Exclusion Criteria:

• Use of an investigational drug or participation in another interventional clinical trial since discontinuation of PREDICT trial

Subjects initially enrolled in PREDICT (NCT 00256126) clinical study and continuing a growth hormone treatment.